Skip to main content

Search
Profile

Nicole Hamblett, PhD

|
Nicole Hamblett, PhD

Academic Title: Research Associate Professor

Research Center: Center for Clinical and Translational Research

Making a Difference

  • Possible Secret Revealed

    A discovery about how Pseudomonas interacts with Staphylococcus points the way to understanding its drug resistance and defeating chronic lung infections.... cont.

Overview

Research Focus Area

Translational Research

Awards and Honors

Award NameAward DescriptionAwarded ByAward Date
National Institute of Health Pre-Doctoral FellowUniversity of Washington Center for AIDS and STD Research, Seattle WA 1996 - 1999
Presidential Scholarship recipientSanta Clara University 1994
George W. Evans Memorial AwardFor outstanding work in mathematical writing and research.Santa Clara University 1994
Alpha Sigma Nu, Jesuit Honor SocietySanta Clara University 1994
Sigma Xi, Scientific Research SocietySanta Clara University 1994
Pi Mu Epsilon, Mathematics Honor SocietySanta Clara University 1994
Dean's ListSanta Clara University 1990 - 1994

Publications

Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
Pediatric pulmonology , Feb. 2012: 125-134
Risk of Post Lung Transplant Renal Dysfunction in Adults with Cystic Fibrosis.
Chest , Jan. 2012
Association of intraventricular hemorrhage secondary to prematurity with cerebrospinal fluid shunt surgery in the first year following initial shunt placement.
Journal of Neurosurgery. Pediatrics , Jan. 2012: 54-63
Risk factors for chronic kidney disease in adults with cystic fibrosis.
American journal of respiratory and critical care medicine , Nov. 2011: 1147-52
Treatment and microbiology of repeated cerebrospinal fluid shunt infections in children.
The Pediatric infectious disease journal , Sept. 2011: 731-5
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
Archives of pediatrics & adolescent medicine , Sept. 2011: 847-56
Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis.
Journal of clinical microbiology , July 2011: 2772-3
Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset.
Expert review of molecular diagnostics , March 2011: 197-206
Open-label, Follow-On Study to Assess Continued Efficacy and Safety of Azithromycin in Children and Adolescents with CF Uninfected with Pseudomonas aeruginosa.
Pediatric Pulmonology (In press) , 2011
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.
The New England journal of medicine , Nov. 2010: 1991-2003
An international randomized multicenter comparison of nasal potential difference techniques.
Chest , Oct. 2010: 919-28
Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
JAMA : the journal of the American Medical Association , May 2010: 1707-15
A pipeline of therapies for cystic fibrosis.
Seminars in respiratory and critical care medicine , Oct. 2009: 611-26
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Contemporary clinical trials , May 2009: 256-68
Reproducibility of spirometry during cystic fibrosis pulmonary exacerbations.
Pediatric pulmonology , Nov. 2008: 1142-6
Shifting patterns of inhaled antibiotic use in cystic fibrosis.
Pediatric pulmonology , Sept. 2008: 874-81
Advancing outcome measures for the new era of drug development in cystic fibrosis.
Proceedings of the American Thoracic Society , Aug. 2007: 370-7
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.
American journal of respiratory cell and molecular biology , July 2007: 57-66
Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
Pediatric pulmonology , July 2007: 610-23
Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.
Pediatric pulmonology , June 2007: 533-41
Association between pulmonary function and sputum biomarkers in cystic fibrosis.
American journal of respiratory and critical care medicine , April 2007: 822-8
Laboratory parameter profiles among patients with cystic fibrosis.
Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , April 2007: 117-23
Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis.
American journal of respiratory and critical care medicine , Oct. 2005: 1008-12
Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease.
Pediatric pulmonology , March 2005: 209-18
Improving the estimation of change from baseline in a continuous outcome measure in the clinical trial setting.
Contemporary clinical trials , Feb. 2005: 2-16
Use of phage display to identify potential Pseudomonas aeruginosa gene products relevant to early cystic fibrosis airway infections.
Infection and immunity , Jan. 2005: 444-52
Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis.
Thorax , Nov. 2004: 955-9
Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial.
Chest , Feb. 2004: 509-21
Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis.
American journal of respiratory and critical care medicine , Dec. 2003: 1471-5
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial.
JAMA : the journal of the American Medical Association , Oct. 2003: 1749-56
Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis.
Vaccine , June 2003: 2448-60
Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.
Chest , May 2003: 1495-502
Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
American journal of respiratory and critical care medicine , March 2003: 841-9
Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.
American journal of respiratory and critical care medicine , Dec. 2002: 1550-5
The cystic fibrosis therapeutics development network (CF TDN): a paradigm of a clinical trials network for genetic and orphan diseases.
Advanced drug delivery reviews , Dec. 2002: 1505-28
Correlation between an in vitro invasion assay and a murine model of Burkholderia cepacia lung infection.
Infection and immunity , March 2002: 1081-6
Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study.
Pediatric pulmonology , Aug. 2001: 122-8
A regression modeling approach for describing patterns of HIV genetic variation.
Biometrics , June 2001: 449-60
Revision surgeries are associated with significant increased risk of subsequent cerebrospinal fluid shunt infection
Pediatric Disease Journal (In press) ,

Research Funding

Grant TitleGrantorAmountAward Date
Rates of Hemoptysis Among Individuals with Cystic Fibrosis Enrolled in Clinical TrialsPharmaxis Ltd.Feb. 1, 2014
Long Term Outcomes After Eradication of Pseudomonas Aeruginosa Among Children Enrolled in EPIC ClinicalNovartis Pharmaceuticals Corp.Dec. 15, 2013
Optimizing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZENIH/NHLBISept. 15, 2013
G551D Observational Study Expanded to Include Additional Genotypes and Extended for Long Term FollowupCystic Fibrosis Foundation TherapeuticsSept. 1, 2013
A Multicenter Study of the Effects of AquADEKs-2 on Markers of Inflammation and Oxidative Stress in CFCystic Fibrosis Foundation TherapeuticsAug. 1, 2012
Pseudomonas Aeruginosa Adaptation During Early CF Airway Infection and TreatmentNIHSept. 11, 2009
Institute of Translational Health SciencesNIH/NCATSSept. 17, 2007

Additional Offices

Seattle Children's Research Institute
CW8-5B Center for Clinical and Translational Research
2001 Eighth Ave
Seattle , WA 98121
206-884-7591

Find a Doctor or Researcher

Find a Doctor or Researcher

Type the first or last name you are searching for or select a specialty.

Doctor or Researcher Name:

More search options